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Bone pain is one of the most common and life-limiting complications of cancer metastasis to 
bone. Although the mechanism of bone pain still remains poorly understood, bone pain is evoked 
as a consequence of sensitization and excitation of sensory nerves (SNs) innervating bone by 
noxious stimuli produced in the microenvironment of bone metastases. We showed that bone is 
innervated by calcitonin gene-related protein (CGRP)+ SNs extending from dorsal root ganglia 
(DRG), the cell body of SNs, in mice. Mice intratibially injected with Lewis lung cancer (LLC) cells 
showed progressive bone pain evaluated by mechanical allodynia and flinching with increased 
CGRP+ SNs in bone and augmented SN excitation in DRG as indicated by elevated numbers of 
pERK- and pCREB-immunoreactive neurons. Immunohistochemical examination of LLC-injected 
bone revealed that the tumor microenvironment is acidic. Bafilomycin A1, a selective inhibitor of 
H+ secretion from vacuolar proton pump, significantly alleviated bone pain, indicating that the 
acidic microenvironment contributes to bone pain. We then determined if the transient receptor 
potential vanilloid 1 (TRPV1), a major acid-sensing nociceptor predominantly expressed on SNs, 
plays a role in bone pain by intratibially injecting LLC cells in TRPV1-deficient mice. Bone pain 
and SN excitation in DRG and spinal dorsal horn were significantly decreased in TRPV1-/- mice 
compared with wild-type mice. Our results suggest that TRPV1 activation on SNs innervating 
bone by the acidic cancer microenvironment in bone contributes to SN activation and bone pain. 





Cancers including breast, prostate and lung cancer show a strong predilection for spreading to 
bone to develop bone metastases (1-3). Cancer metastasis to bone is associated with 
debilitating and life-limiting skeletal complications such as pathological fracture and spinal cord 
compression (4-6). In addition, bone pain is also one of the most common and devastating 
complications of bone metastasis and more than 70% of advanced cancer patients with bone 
metastases suffer from bone pain (4,7-9). Bone pain is associated with reduced performance 
status, increased fatigue, anxiety and depression, and reduced health quality of life, leading to 
increased morbidity and mortality (7-9). Treatment of bone pain is thus an important goal in the 
management of patients with advanced cancer who develop bone metastases. However, our 
understandings of the mechanism(s) underlying cancer-induced bone pain, which is required to 
logically develop effective treatments, are limited and currently-available therapies are 
inadequate and ineffective or often cause uncomfortable adverse effects (10). 
Bone pain is induced as a consequence of sensitization and excitation of sensory nerves (SNs) 
innervating bone by mechanical, chemical and/or thermal noxious stimuli that are produced 
under complex interactions among cancer cells, bone cells (osteoclasts, osteoblasts and 
osteocytes), bone marrow stromal cells and immune cells (11,12). Although the precise 
mechanism by which these noxious stimuli excite SNs and evoke bone pain remains unclear, 
clinical observations that bone-targeting agents including bisphosphonates and denosumab 
significantly relieve bone pain in cancer patients with bone metastases (13) indicate a critical role 
of osteoclasts in the pathophysiology of cancer-induced bone pain. Osteoclasts, which play a 
central role in the development and progression of bone metastasis by establishing the vicious 
cycle with metastatic cancer cells (1,14,15), destroy bone by releasing protons via the plasma 
membrane a3 isoform vacuolar proton pump (16), thereby creating acidic microenvironments in 
bone metastases. Further, invasive and metastatic cancer cells show increased expression of 
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plasma membrane vacuolar proton pump (17,18) through which protons are actively extruded to 
avoid intracellular acidification due to elevated aerobic glycolysis (Warburg effect) (19). We 
reported that highly metastatic B16-F10 melanoma cells express increased plasma membrane 
vacuolar proton pump (20). Thus, the extracellular microenvironment of bone metastases is 
acidic. It is noted that acid/proton is a potent inducer of pain (21). These results collectively 
suggest that the acidic cancer microenvironment in bone plays a role in the induction of bone 
pain.  
Peripheral SNs express nociceptors to recognize and transduce local noxious stimuli into 
electrochemical signals (21). The nociceptors transmit these noxious signals to the central 
nervous system (CNS) and brain via the dorsal root ganglion (DRG), the cell body of primary 
afferent SN fibers innervating peripheral tissues such as bone (22). The specific and major 
acid-sensing nociceptor of SNs is the transient receptor potential channel-vanilloid subfamily 
member 1 (TRPV1) (23). TRPV1, a member of TRP ion channel superfamily, is a Ca2+ channel 
that is predominantly expressed on nociceptive SNs and activated by capsaicin, heat (>43ºC) 
and acid (<pH 6.0) (24). TRPV1-/- mice showed little pain behavior in response to capsaicin, 
heat and inflammation (25). Of interest, a recent study reported that TRPV1-/- mice live longer 
with increased metabolic health than do wild-type (WT) mice, suggesting that reduced pain 
responses due to the absence of TRPV1 may increase longevity (26).  
In the present study, we found that intratibial injection of Lewis lung cancer (LLC) cells in mice 
induced bone pain with increased number of TRPV1+ SNs in bone and excitation in DRG.  
Inhibition of the development of acidic microenvironment by bafilomycin A1 decreased bone pain. 
Importantly, SN excitation and bone pain following intratibial injection of LLC cells are 
significantly decreased in TRPV1-/- mice compared to wild-type (WT) mice. 
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MATERIALS AND METHODS 
 
Reagents  
RPMI1640, bovine serum albumin (BSA) and rabbit anti-CGRP antibody were purchased from 
Sigma (St Louis, MO). Fetal calf serum (FCS) was from Asahi Glass Techno Corp. (Tokyo, 
Japan). Fluoro-ruby (Dextran tetramethylrhodamine 10,000 MW), Alexa Fluor 488-conjugated 
goat anti-rabbit IgG antibody, and 3-(2,4-dinitroanillino)-3'-amino-N-methyldipropylamine (DAMP) 
were purchased from Molecular Probes (Eugene, OR). Rabbit anti-dinitrophenol antibody was 
purchased from Oxford Bio Lab (Oxford, UK). FITC-conjugated anti-guinea pig IgG, 
Cy3-conjugated anti-guinea pig IgG, Cy5-conjugated anti-rabbit IgG and biotinylated anti-guinea 
pig IgG antibodies were purchased from Jackson Immuno Research Laboratories Inc. (West 
Grove, PA). Guinea pig anti-CGRP antibody was from Eurodiagnostica (Malmö, Sweden). 
Normal swine serum (NSS) and biotinylated swine anti-rabbit IgG antibody were purchased from 
Dako, (Copenhagen, Denmark). ABC complex, 3,3'-diaminobenzidine (DAB) substrate kit and 
Vectorshield were purchased from Vector Laboratories, Inc.(Burlingame, CA). Rabbit 
anti-phosphorylated ERK antibody was purchased from Cell Signaling Technology, (Danvers, 
MA). Rabbit anti-c-fos and rabbit anti-TRPV1 antibodies were purchased from Oncogene 
Science (Cambridge, MA, USA). Bafilomycin A1 was purchased from Wako Pure Chemical 
Industries, Ltd. (Osaka, Japan). Carboxylate cement (dental resin) was purchased from Unifast 
Trad, GC Dental Products Co., (Aichi, Japan). Silk threads were from Ethicon (Somerville, NJ) 
 
Cell culture  
Mouse LLC cells were purchased from Cell Resource Center for Biomedical Research, Tohoku 
University (Miyagi, Japan) and cultured in RPMI1640 medium supplemented with 10% FCS, 100 
µg/ml kanamycin sulfate (Meiji Seika, Ltd., Tokyo, Japan) in a humidified atmosphere of 5% CO2. 





C57BL/6 mice (4-6 week-old, 20-25 g) were purchased from Japan SLC Inc. (Hamamatsu, 
Japan). TRPV1-/- mice were kindly provided by Dr. Julius of the Department of Cellular and 
Molecular Pharmacology at UCSF. Mice were maintained on a 12:12 h dark-light cycle with food 
and water. All experiments were conducted in accordance with the ethical guidelines of the 
International Association for the Study of Pain (28) and approved by the Institutional Animal Care 
and Use Committee of Osaka University Graduate School of Dentistry. 
 
Intratibial injection of LLC cells  
All procedures were performed under general anesthesia with pentobarbital (0.05 mg/g body 
weight; Dainippon Pharmaceutical Co., Ltd., Osaka, Japan). 
Surgical procedures were performed as described previously (29). Following anesthesia, mice 
were placed abdominal side up. A one cm-long rostro-caudal incision was made in the skin over 
the top half of the right tibiae. The tibiae were carefully exposed with minimal damages to the 
muscle or blood vessels. Using a 30-gauge needle, bone was pierced 2 mm below the knee joint 
distal to the epiphyseal growth plate and needle was inserted into the marrow cavity of tibiae. 
The 30-gauge needle was then removed and replaced with a 29-gauge needle, and LLC cells (1 
x 105) in 10 µl PBS were slowly injected through a 25 µl Hamilton syringe needle that was 
inserted in the inner hole of the 29-gauge needle to prevent leakage of cells. Sham mice 
received PBS without cells. The injection hole on bone was closed using carboxylate cement and 
skin wound using silk threads. In some experiments, mice were treated with bafilomycin A1 (25 
μg/kg/day) subcutaneous injection once a day from day 7 to day 14. Control mice received PBS. 
Tumor growth in bone was monitored weekly by X-ray. Mice in which LLC cells in the bone 




Assessment for bone pain  
Bone pain was determined by widely-used pain-related behavior tests including 
stimulus-dependent thermal plantar hyperalgesia test and stimulus-independent spontaneous 
hind-limb lifting test (30). A few days prior to intratibial LLC cell inoculation, mice were subjected 
to these tests to obtain the data of control behavior. Tests were repeated three times by a single 
investigator in a blind manner. Mice in which cancer cells broke out the cortex and spread 
on periosteum were not included in the tests, so that the bone pain observed here 
represents bone pain that is primarily induced by LLC cells within bone marrow. 
 
Thermal plantar hyperalgesia test 
Plantar test (Plantar test, 7370; Ugo Basile, Comerio, Italy) was performed as described 
previously (31). Mice were placed in a clear plastic chamber with a glass floor unrestrained and 
allowed to acclimate to their environment for 30 min before testing. Radiant heat source was 
then positioned under the glass floor directly beneath the hind-paw. A photoelectric cell aimed at 
the aperture-detected light reflects from the paw and turned off the electronic clock when paw 
movement interrupted the reflected light. Time required for mice to withdraw their paw of 
LLC-injected tibiae in response to radiant heat stimulation was determined using an electronic 
clock circuit connected with a microcomputer.  
 
Hind-limb lifting (Flinching) test  
Mice were placed on a glass floor at room temperature (32). After an acclimation for 30 min, mice 
were determined for cumulative duration or frequency of repetitive and spontaneous flinching of 
the LLC-injected hind-limbs (rapid lifting of the entire hind-limb that begins with hip flexion and 





Retrograde tracing was performed to verify that SNs in lumbar DRG (L3-L5) innervate tibial bone 
marrow cavity according to the methods described with modifications (33). Mice were 
anesthetized and the retrograde neural tracer, 5% fluoro-ruby (Dextran tetramethylrhodamine 
10,000 MW) (4 μl), was injected into the medullary cavity of tibiae. The tracer injection site was 
covered with carboxylate cement. Two days after the tracer injection, animals were anesthetized 
with pentobarbital and perfused through left cardiac ventricle with 0.1 M PBS followed by 4% 
paraformaldehyde fixative as we reported (34). DRGs (L3-5) were subsequently harvested and 
processed for the preparation of cryostat sections and double-stained using a rabbit anti-TRPV1 
antibody (1:500) and guinea pig anti-CGRP antibody (1:5000). Secondary antibodies conjugated 
with Cy5 and FITC (1:500) were used to distinguish the immuno-labeling from the labeling with 
fluoro-ruby. Stained sections were examined under a confocal laser scanning microscope 
(LSM510, Ver 3.2, Carl Zeiss). 
 
Immunohistochemistry (IHC) 
Dorsal root ganglion (DRG) and spinal cord  
At the end of experiments, mice were anesthetized, perfused and DRG (L3-L5) and spinal cord 
(lamina II/III) were removed, post-fixed overnight in the same fixative and then cryo-protected in 
20 % sucrose overnight at 4°C. Sections (10-30 μm) were cut on a cryostat. Following rinsing 
with PBS, sections were treated with PBS containing 0.3% H2O2 to block endogenous 
peroxidase activity for 30 min at room temperature (RT), rinsed with PBS several times, treated 
with PBS containing 1 % normal swine serum and 1% BSA for 30 min, and then incubated with a 
rabbit anti-TRPV1 (1:500), rabbit anti-CGRP (1:10,000), phosphorylated ERK (1:1,000) or c-Fos 
(1:2,000) overnight at RT. These sections were then incubated with biotinylated swine anti-rabbit 
IgG (1:500) and subsequently with the ABC complex at RT for 90 min each. The 
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antigen-antibody reaction sites were visualized by incubation with 0.04% 3,3'-diaminobenzidine 
(DAB) and 0.003% H2O2 in 0.05 M Tris–HCl buffer (pH 7.5) intensified with 0.1% nickel 
ammonium sulfate. The primary and secondary antibodies were diluted with PBS containing 1 % 
NSS and 1 % BSA. The immunostained sections were mounted onto gelatin-subbed glass slides, 
dehydrated through an ascending series of ethanol, cleared, and cover-slipped with Permount 
and enumerated for numbers of pERK- and c-fos-immunoreactive SNs under a light microscope.  
 
Bone 
After fixation with 10 % neutral formalin, bones were harvested and decalcified in 10 % EDTA for 
2 weeks. Sections (30 μm) were cut on a cryostat, rinsed with PBS several times, treated with 
PBS containing 1 % NSS and 1 % BSA for 30 min, and then incubated with a rabbit anti-TRPV1 
(1:100) and guinea pig anti-CGRP (1:2,000) overnight at RT. These sections were then 
incubated with Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:500) and Cy3-conjugated goat 
anti-guinea pig IgG (1:500) at RT for 90 min. The immunostained sections were cover-slipped 
with Vectorshield. Sections were examined for CGRP+ and TRPV1+ SNs under a confocal laser 
scanning microscope. The images were captured with CCD camera software (AxioCom Ver. 4.6; 
Carl Zeiss), and transferred to Adobe Photoshop.  
Histochemical staining for tartrate-resistant acid phosphatase (TRAP) was also performed and 
numbers of TRAP+ osteoclasts were enumerated as we described previously (35). 
 
Detection of acidic microenvironment 
At day 14, 300 μg 3-(2,4-dinitroanillino)-3'-amino-N-methyldipropylamine (DAMP), which 
selectively accumulates in acidic microenvironments, in PBS (1.2 mg/ml) was administered via 
the carotid artery over 30 min to cancer-injected mice as described previously (36). After fixation 
with 4 % paraformaldehyde through left cardiac ventricle, bones were decalcified in 10 % EDTA 
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for 2 weeks. Paraffin sections were made, incubated with rabbit anti-dinitrophenol antibody (1:50, 
Oxford Bio Lab), which cross-reacts with DAMP, overnight at RT and then with the ABC complex. 
The antigen-antibody reaction sites were visualized by incubation with 0.04 % 
3,3'-diaminobenzidine (DAB) and 0.003 % H2O2 in 0.05 M Tris–HCl buffer (pH 7.5) intensified 
with 0.08–0.1 % nickel ammonium sulfate. Sections were counterstained with methyl green  
 
Statistical analysis  
The data were analyzed by one-way ANOVA followed by Fisher’s PLSD post-hoc test (StatView; 
SAS Institute Inc., Cary, NC). P values of <0.05 were considered statistically significant. All of the 






Innervation of SNs in bone 
Data are accumulating that bone is densely innervated by SNs (33,37-40). Consistent with these 
earlier studies, our IHC examination using an antibody for calcitonin gene-related peptide 
(CGRP), which is a widely-used marker for SN (41), demonstrated that CGRP-positive (CGRP+) 
SNs accumulate at periosteum, extending into the medullary cavity through mineralized bone 
(Figure 1A, arrows). Further, CGRP+ SNs (Figure 1B, arrows) locate in the close proximity of 
TRAP+ osteoclasts (Figure 1B, arrow head) in bone. These results suggest that SNs can be 
excited by osteoclasts during bone destruction and are consistent with the clinical observations 
that the specific inhibitors of osteoclasts, bisphosphonates and denosumab, relieve bone pain in 
cancer patients with bone metastases (13). Of note, CGRP+ SNs in bone co-expressed TRPV1 
(Figure 1C), suggesting that CGRP+ SNs are excited to evoke bone pain by acidic bone 
microenvironments via TRPV1. Retrograde tracing using fluoro-ruby reveals that the bone 
marrow cavity of tibiae is innervated by fluoro-ruby+, CGRP+ and TRPV1+ SNs, demonstrating 
that these SNs extend from L3-L5 DRG (Figure 1D).      
 
Animal model of cancer-induced bone pain 
LLC cells inoculated into the medullary cavity of right tibiae developed osteolytic lesions on X-ray 
(Figure 2A, right, arrow) and occupied intramedullary cavity (Figure 2A, left, asterisks) over 14 
days. In parallel with intramedullary growth of LLC cells, numbers of TRAP+ osteoclasts in tibiae 
were increased (Figure 2B). Importantly, we found that numbers of CGRP+ and TRPV1+ SNs 
were also increased in tibiae injected with LLC cells (Figure 2C). Other investigators also 
reported that sprouting of SNs is increased in the presence of tumor in bone (39,42). More 
importantly, mice intratibially injected with LLC cells began to demonstrate thermal hyperalgesia 
at day 7 compared with sham mice (Figure 2D) that continuously progressed until day 14. Further, 
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these mice also exhibited increased frequency (Figure 2E) and duration (Figure 2F) of lifting of 
their hind-limbs (flinching) injected with LLC cells compared with sham mice. Sham mice (Figure 
2D, 2E & 2F) exhibited no thermal hyperalgesia and lifting of their hind-limbs. Left tibiae of 
LLC-injected mice had no evidence of bone pain (data not shown), demonstrating that bone pain 
is associated with local LLC colonization rather than a systemic effect of LLC cells. These results 
show that LLC cells intratibially injected in mice promote SN sprouting and progressively induce 
bone pain. 
 
Role of acidic bone microenvironment in cancer-induced bone pain 
To determine if LLC cells growing in bone develop acidic microenvironment in bone, we 
administered DAMP, which selectively accumulates in acidic compartments and is 
immunohistochemically detected by anti-dinitrophenol antibody, which cross-reacts with DAMP 
(36), to LLC-injected mice. As shown in Figure 3A, the microenvironments where LLC cells are 
progressively growing showed DAMP accumulation and thus are acidic. Further, consistent with 
our previous report (43), the microenvironments associated with TRAP+ osteoclasts were also 
acidic (Figure 3B). The pH value of the microenvironment associated with LLC cells and 
osteoclasts was unknown. 
To determine the role of the acidic microenvironment developed in LLC-growing bone in the 
induction of bone pain, we tested the selective inhibitor of vacuolar proton pump, bafilomycin A1, 
which, we reported, reduces inflammatory bone pain (44), in LLC-injected mice. We found that 
bafilomycin A1 significantly decreased thermal hyperalgesia (Figure 3C) and flinching (Figure 
3D). These results suggest that bone pain is induced by the acidic microenvironment created as 
a result of LLC tumor progression in bone. It should be, however, noted that bafilomycin A1 only 
partially decreased thermal hyperalgesia, suggesting that mechanisms other than acidic cancer 




Role of TRPV1 in cancer-induced bone pain   
We then determined if the acid-sensing nociceptor TRPV1 is involved in the induction of bone 
pain in mice carrying LLC cancer in bone. To approach this, we intratibially injected LLC cells in 
TRPV1-/- mice and WT mice and conducted pain behavior tests in these mice. LLC tumor growth 
in tibiae in TRPV1-/- mice was not different from that in WT mice during 14 day experimental 
period (data not shown). Intratibial injection of LLC cells induced thermal hyperalgesia (Figure 
4A) and flinching (Figure 4C and 4D) in WT mice. Importantly, however, TRPV1-/- mice showed 
no thermal hyperalgesia (Figure 4B) and significantly decreased flinching (Figure 4C and 4D).  
These results suggest that TRPV1 on SNs plays a critical role in LLC cancer-induced bone pain. 
 
Role of TRPV1 in SN excitation  
Since cancer-induced bone pain was decreased in TRPV1-/- mice, we next determined if SN 
excitation is also reduced in TRPV1-/- mice by assessing the expression of phosphorylated 
extracellular signal-regulated protein kinase (pERK) in DRG (the primary afferent neurons) and 
c-fos in the spinal dorsal horn (the secondary afferent neurons). pERK is a widely used molecular 
indicator for neural activation by noxious stimuli (45) and c-fos is a marker for efficient detection 
of SNs excited in response to nociceptive stimuli (46). 
IHC showed that the number of pERK+ neurons in DRG was significantly increased following 
intratibial injection of LLC cells into WT mice (Figure 5A, 5B and 5E). In contrast, intratibial 
injection of LLC cells did not increase the number of pERK+ neurons in DRG in TRPV1-/- mice 
(Figure 5C, 5D and 5E). 
Similarly, WT mice showed significant increase in c-fos+ neurons in spinal dorsal horn following 
intratibial injection of LLC cells (Figure 6A, 6B and 6E), whereas no change in the number c-fos+ 
neurons in spinal dorsal horn was seen in TRPV1-/- mice intratibially injected with LLC cells 





Mechanism of cancer-induced bone pain is poorly understood and bone pain is undertreated in 
cancer patients with bone metastases (7-9). Since progression of bone metastases is modulated 
by the interactive co-operations (vicious cycle) between bone-colonizing cancer cells and 
bone-destroying osteoclasts with supports of other bone cells including osteoblasts and 
potentially osteocytes (1,14,15), it is likely that these players also contribute to the 
pathophysiology of bone pain associated with bone metastases. In the present study, we found 
that cancer cells colonizing bone and bone-resorbing osteoclasts play a critical role in the 
induction of bone pain through creation of an acidic tumor microenvironment. Our results 
demonstrated that treatment of LLC tumor-bearing mice with bafilomycin A1, which, we recently 
reported, blocks the development of acidic microenvironment in cancer-colonized bone through 
inhibiting proton release via the plasma membrane vacuolar proton pump (43), significantly 
reduced bone pain. These results suggest that bone pain associated with bone metastasis is 
attributable to the acidic tumor microenvironment created by increased proton release by cancer 
cells and bone-destroying osteoclasts.   
These results led us to determine if the acid-sensing nociceptor TRPV1 expressed on SNs is 
involved in the pathophysiology of bone pain associated with the acidic tumor microenvironment 
by a genetic approach using TRPV1-/- mice. Several earlier studies reported that inhibition of 
TRPV1 activation using selective TRPV1 antagonists reduced bone pain in preclinical animal 
models (47-50), demonstrating a critical role of TRPV1 in bone pain. However, one concern in 
these pharmacological studies is that the results obtained could be due to off-target effects of 
antagonists tested. In this study, we found that SN excitation as determined by the number of 
pERK+ SNs in DRG and c-fos+ SNs in spinal dorsal horn was significantly reduced and bone pain 
was also significantly decreased in TRPV1-/- mice intratibially injected with LLC cells compared 
with WT mice. Our genetic approach using TRPV1-/- mice thus provide the concrete evidence 
that TRPV1 contributes to SN excitation and bone pain induced in response to the acidic tumor 
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microenvironment in bone.  
It has been long proposed that the periosteum is the primary site from which bone pain elicits (7). 
However, cancers growing within bone marrow or mineralized bone often induce bone pain in the 
absence of evident periosteal involvement (38), indicating the innervation of SN fibers in 
non-periosteal sites in bone. Consistent with this notion, our IHC showed that CGRP+ SN fibers 
not only accumulate at the periosteum but also terminate into the bone marrow cavity running 
through mineralized bone. Importantly, we found that cancer colonization increased sprouting of 
these bone-innervating SN fibers and up-regulated excitation of these SN fibers at DRG (L3-L5) 
and spinal dorsal horn via TRPV1 activation in response to the acidic microenvironment of 
cancer-colonized bone. Consequence of these changes in SNs is obviously parts of the 
mechanism underlying cancer-induced bone pain. Thus, bone is an organ in which SNs heavily 
innervate and show noxious responses to changes in the microenvironment resulting from 
cancer colonization and osteoclastic bone destruction and provides a unique model to study the 
pathophysiology of cancer-induced pain. 
Bone fractures are one of the major causes of bone pain (7) and the bone pain observed in this study 
could result from pathologic bone microfractures associated with increased osteolysis. Unfortunately, 
however, the behavior tests and biochemical determinations used in this study do not allow us to 
distinguish bone pain due to bone microfractures from that caused by acidic tumor microenvironment. 
Our results show that mice intratibially injected with LLC cells began to manifest nocifensive 
behaviors at day 7 at which bone destruction by LLC cells was minimum on X-ray and evident bone 
microfractures were not verified by histology. These results suggest that contribution of bone 
microfractures to bone pain is minimal in early stages of the disease in this model. However, at day 14 
at which bone destruction overtly advanced, bone fractures most likely caused to increase bone pain. 
We think that contribution of bone fractures to cancer-induced bone pain is stage-dependent at least 
in this model. 
Intratibial injection of cancer cells may mechanically disrupt the normal innervation of bone 
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marrow. In fact, it should be noted that sham mice intratibially injected with PBS showed thermal 
hyperalgesia at day 1 and 4, suggesting that traumatic injuries by needle insertion into the 
medullary cavity caused thermal hyperalgesia. However, the thermal hyperalgesia was no longer 
seen at day 7 and thereafter, indicating that the injuries were healed by day 7. Thus, thermal 
hyperalgesia and flinching observed in LCC-injected mice after day 7 are ascribed to tumor 
progression, representing cancer-induced bone pain. 
In conclusion, our results show that TRPV1 activation by the acidic cancer microenvironment in 
bone promotes SN sprouting and excitation, leading to bone pain. Blocking TRPV1 activation by 
acidic cancer microenvironment may be a novel and potential therapeutic approach for 
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A. Innervation of CGRP+ SN in bone. Sections (30µm thickness) of mouse bone were 
immunostained with anti-CGRP antibody, counterstained with methyl green and 
examined under a light microscope (x 100). Arrows: CGRP+ SNs  
B. Spatial relationship between SNs and osteoclasts in bone. Sections were immunostained 
with anti-CGRP antibody and subsequently stained for TRAP (x 400). Arrows: CGRP+ 
SNs; arrowhead: TRAP+ osteoclast. 
C. Innervation of CGRP+ and TRPV1+ SN in bone. Sections were immunostained with 
anti-CGRP and anti-TRPV1 antibody and examined under a confocal laser scanning 
microscope (x 200). Arrows: CGRP+ and TRPV+ SN. 
D. Retrograde tracing of SN fiber from bone to DRG. The retrograde neural tracer, 
fluoro-ruby, was injected into the medullary cavity of tibiae. Two days after tracer injection, 
DRGs (L3-5) were harvested and subjected to immunohistochemical analyses. Sections 
of DRG were immunostained with anti-CGRP and anti-TRPV1 antibody and examined 
under a confocal laser scanning microscope (x 400). Arrow: Fluoro-ruby+, TRPV1+, and 
CGRP+ SN fiber. 
 
Figure 2 
A. Radiograph and histology (x 40, HE) of tibiae injected with LLC cells at day 7 and 14. 
Arrows: osteolytic lesions. Asterisks: LLC tumor.  
B. Increase in numbers of TRAP+ osteoclasts in bone injected with LLC cells over time.  
* p<0.05 vs day 0 (mean ± SE, n=5). 
C. Increase in numbers of CGRP+ and TRPV1+ SN fibers in bone injected with LLC cells. 
Mice were sacrificed at day 14 and sections of bone were immunostained with anti-CGRP 
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and anti-TRPV1 antibody. *p<0.01 vs sham (mean ± SE, n=5). 
D. Thermal hyperalgesia in mice intratibially injected with PBS (sham) or LLC cells (tumor). 
Assay was conducted in a blind manner, *p<0.05 vs sham (mean ± SE, n=10). 
E. Frequency of flinching in mice injected with PBS (sham) or LLC cells (tumor) intratibially 
during 10 min observation. *p<0.05 vs sham (mean ± SE, n=10).  
F. Duration of flinching in mice injected with PBS (sham) or LLC cells (tumor) intratibially 
during 10min observation. *p<0.05 vs day sham (mean ± SE, n=10). 
  
Figure 3 
A. Acidic microenvironment of LLC tumor in bone. Mice were injected with DAMP before 
sacrifice at day 14. Sections of bone were incubated with rabbit anti-dinitrophenol 
antibody and counterstained with methyl green (x 200). Brown indicates acidic area. 
B. Acidic microenvironments associated with TRAP+ osteoclasts (x 200). 
C. Effects of bafilomycin A1 on thermal hyperalgesia in mice injected with PBS (sham) or 
LLC cells (tumor) intratibially. Bafilomycin A1 (25 μg/kg/day, sc) was given to mice once a 
day from day 7 to day 14. *p<0.05 vs control sham group (mean ± SE, n=8). #p<0.05 vs 
control tumor group (mean ± SE, n=8). 
D. Effects of bafilomycin A1 on the frequency of flinching in mice injected with PBS (sham) 
or LLC cells (tumor) intratibially. Flinching test was conducted at day 14. *p<0.05 vs 
control (mean ± SE, n=10).   
 
Figure 4 
A. Thermal hyperalgesia in WT mice intratibially injected with PBS (sham) or LLC cells (tumor). 
*p<0.05 vs sham (mean ± SE, n=10). 




C. Frequency of flinching in WT and TRPV1-/- mice intratibially injected with PBS (sham) or LLC 
cells (tumor) during 10min observation at day 14. *p<0.05 vs WT (mean ± SE, n=10). 
D.  Duration of flinching in WT and TRPV1-/- mice intratibially injected with PBS (sham) or LLC 
cells (tumor) during 10min observation at day 14. *p<0.01 vs WT (mean ± SE, n=10). 
 
Figure 5 
A. IHC of pERK+ neurons (arrow) in DRG in WT mice intratibially injected with PBS. DRGs 
(L3-L5) ipsilateral to LLC cell-injected tibiae were harvested at sacrifice at day 14. Sections 
were stained with anti-pERK antibody (1:1,000) overnight at RT (x 100). 
B. IHC of pERK+ neurons (arrows) in DRG in WT mice intratibially injected with LLC cells. 
C. IHC of pERK+ neurons (arrow) in DRG in TRPV1-/- mice intratibially injected with PBS. 
D. IHC of pERK+ neurons (arrow) in DRG in TRPV1-/- mice intratibially injected with LLC cells. 
E. Numbers of pERK+ neurons/CGRP+ SNs in DRG. *p<0.05 vs sham (mean ± SE, n=10), 
#p<0.05 vs WT tumor group (mean ± SE, n=8). 
 
Figure 6 
A. IHC of c-fos neurons (arrow) in spinal dorsal horn in WT mice intratibially injected with PBS. 
Spinal dorsal horns ipsilateral to LLC cell-injected tibiae were harvested at sacrifice at day 14. 
Sections were stained with anti-c-fos antibody (1:2,000) overnight at RT (x 100). 
B. IHC of c-fos neurons (arrows) in spinal dorsal horn in WT mice intratibially injected with LLC 
cells. 
C. IHC of c-fos neurons (arrow) in spinal dorsal horn in TRPV1-/- mice intratibially injected with 
PBS. 
D. IHC of c-fos neurons (arrow) in spinal dorsal horn in TRPV1-/- mice intratibially injected with 
LLC cells. 
E. Numbers of c-fos neurons/CGRP+ SNs in spinal dorsal horn. *p<0.05 vs sham (mean ± SE, 
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